Longevity Research Stack: NAD+, Senolytic Compounds & Longevity Peptide Overview

A research deep-dive into NAD+ precursors, senolytic compounds, and longevity peptides — including Epitalon, MOTS-c, SS-31, and thymosin alpha-1.

TL;DR

• Longevity research has converged on three complementary mechanisms: NAD+ restoration, senescent cell clearance, and peptide-based signaling modulation.
• NAD+ levels decline ~50% from age 40–60, impairing mitochondrial function and DNA repair.
• Senolytic compounds selectively eliminate senescent "zombie cells" that secrete pro-inflammatory SASP factors.
• Longevity peptides like Epitalon and MOTS-c target telomere biology and mitochondrial signaling respectively.

Disclaimer: For educational and research purposes only — not medical advice.

The study of longevity biology has moved rapidly from theoretical frameworks to compound-specific research protocols. Where previous generations of "anti-aging" research focused on antioxidant theory — now largely considered incomplete — contemporary longevity science targets specific molecular hallmarks: NAD+ depletion, cellular senescence accumulation, mitochondrial dysfunction, and epigenetic drift. This article provides a structured overview of the key compound classes being researched in this space, the mechanisms behind them, and what the current evidence actually supports.

NAD+ Biology: Why Depletion Matters and How NMN/NR Address It

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell. Its primary roles include serving as an electron carrier in the mitochondrial electron transport chain, acting as a substrate for sirtuins (SIRT1–7) that regulate gene expression and DNA repair, and fueling PARP enzymes involved in DNA damage response. The problem: NAD+ levels fall significantly with age. Data from multiple studies suggests a ~50% decline between ages 40 and 60 in human tissue samples, with skeletal muscle and liver showing the steepest drops.

This decline has downstream consequences. Without adequate NAD+, SIRT1 activity falls, accelerating epigenetic drift. PARP enzymes compete for limited NAD+, leaving other pathways undersupplied. Mitochondrial efficiency drops, contributing to the bioenergetic decline characteristic of aging.

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two most-researched oral NAD+ precursors. Both work via the NAD+ salvage pathway, though at different steps. A 2023 human trial by Yoshino et al. demonstrated that 300mg/day NMN supplementation increased muscle NAD+ metabolite levels and improved insulin sensitivity in prediabetic women. NR studies have shown similar NAD+ elevation in blood, with a 2018 Trammell et al. study in Cell Metabolism reporting dose-dependent NAD+ increases at 100–300mg/day.

Research note: A 2020 paper in Nature Metabolism (Airhart et al.) raised questions about NR's metabolic fate in humans, noting that much of the oral NR dose is catabolized to nicotinamide before reaching tissues. This does not negate efficacy but is relevant for those designing precise NAD+ research protocols.

Senolytic Compounds: Clearing Senescent Cells to Reduce SASP Burden

Cellular senescence is a state in which damaged cells exit the cell cycle but resist apoptosis. These "zombie cells" accumulate with age and secrete a pro-inflammatory cocktail called the senescence-associated secretory phenotype (SASP) — cytokines, matrix metalloproteinases, and growth factors that damage surrounding tissue and propagate inflammation. In young organisms, senescent cells are efficiently cleared by the immune system. With age, this clearance becomes impaired.

The landmark work from James Kirkland's group at the Mayo Clinic established that targeted clearance of senescent cells — senolytics — could reverse multiple age-related pathologies in mice. Their dasatinib + quercetin (D+Q) combination showed dramatic results: improvements in physical function, reduced frailty, extended healthspan. A 2019 paper in EBioMedicine from Hickson et al. reported the first human trial of D+Q in patients with idiopathic pulmonary fibrosis, showing reduced SASP biomarkers and improved physical performance.

Fisetin emerged from a 2018 Yousefzadeh et al. paper in EBioMedicine as the most potent natural senolytic tested — outperforming quercetin, kaempferol, and other flavonoids in clearing senescent cells in mouse models. It extended median lifespan by 10% in aged mice. Current human research involves the AFFIRM-LITE trial.

Researchers using natural senolytics typically reference a "pulse dosing" approach from the Kirkland literature — high-dose fisetin (20mg/kg in mice, translating to approximately 1,400mg in a 70kg human using standard allometric scaling) administered for 2–3 consecutive days per month rather than daily. Daily dosing has not been shown to provide additional benefit and may impair normal cell death processes.

Longevity Peptides: Epitalon, MOTS-c, SS-31, and Thymosin Alpha-1

Peptide research in the longevity space occupies a distinct niche: rather than supplementing substrates or clearing dysfunctional cells, these compounds work as signaling molecules that influence gene expression, mitochondrial function, and immune regulation.

Epitalon is the most studied longevity peptide by publication count, primarily through the work of Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a tetrapeptide (Ala-Glu-Asp-Gly) that stimulates pineal gland production of melatonin and has demonstrated telomerase activation in somatic cell cultures. A 2004 paper in Annals of the New York Academy of Sciences reported increased telomere length in patients treated with Epitalon over a 3-year protocol. Importantly, much of this research is from a single group and has not been widely replicated in Western institutions. See the full Epitalon research database entry for citation details.

MOTS-c is a 16-amino acid peptide derived from the mitochondrial genome — specifically encoded in the 12S rRNA. Research from Pinchas Cohen's lab at USC has shown that MOTS-c regulates glucose metabolism via AMPK signaling, decreases with age in human plasma, and that supplementation extends lifespan and improves physical function in aged mice. A 2021 paper in Nature Communications demonstrated that MOTS-c levels correlate inversely with age and metabolic disease in human cohort data. See the MOTS-c database entry for the full research summary.

SS-31 (Elamipretide) is a mitochondria-targeted antioxidant tetrapeptide that concentrates in the inner mitochondrial membrane, where it protects cardiolipin from peroxidation and maintains cristae structure. Multiple animal studies have shown reversal of age-associated mitochondrial dysfunction with SS-31 treatment. Human trials are ongoing in heart failure and Barth syndrome.

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide derived from thymosin fraction 5. It modulates T-cell function and dendritic cell activity, and is used clinically in several countries (as Zadaxin) for hepatitis B/C, cancer immunotherapy adjuvant, and immunodeficiency. Its relevance to longevity research lies in immune aging (immunosenescence): declining thymic output and T-cell dysfunction are hallmarks of aging immunity. See the thymosin alpha-1 database entry.

Suggested Research Protocol by Compound Class

The following table is a research reference framework — not a clinical dosing guide. Values are derived from published literature or standard research practice.

For peptide preparation guidance, see the reconstitution calculator. For half-life and dosing timing, see the half-life calculator.

Frequently Asked Questions

Q: Can NAD+ precursors and senolytics be combined safely in a research protocol? A: The combination has not been formally tested in clinical trials. In animal models, NAD+ precursors and senolytics appear to target complementary mechanisms — metabolic restoration versus cell clearance — suggesting potential additive effects. The most common research approach is to run NAD+ supplementation continuously and add senolytic pulse dosing once monthly. There is no published human safety data on the combination at high doses.

Q: Is Epitalon's telomerase research credible? A: The telomerase activation data from Khavinson's group is published in peer-reviewed journals, but the research comes almost exclusively from one institute and has not been independently replicated by Western groups to the same extent. The in vitro and animal data are reasonably compelling; the human longitudinal data is less robust by modern clinical trial standards. This is not unusual for Russian peptide research, which followed a different regulatory and publication track than Western pharmaceutical development.

Q: What biomarkers should a longevity researcher track? A: Published longevity research typically uses a combination of: NAD+ metabolite levels (blood or urine), inflammatory markers (CRP, IL-6, TNF-α), p16INK4a expression as a proxy for senescent cell burden, telomere length (though this is variable and expensive to measure accurately), and biological age clocks (Horvath DNA methylation clock or DunedinPACE). Tracking all of these is research-grade complexity, but even a basic metabolic panel, CRP, and HbA1c provides useful baseline data.

Q: How does SS-31 differ from other mitochondria-targeted antioxidants like MitoQ? A: MitoQ uses a triphenylphosphonium (TPP) cation to target ubiquinone to the mitochondrial membrane. SS-31 uses a different mechanism: its alternating aromatic and basic residues allow it to localize to cardiolipin on the inner mitochondrial membrane specifically, where it acts as an electron carrier and reduces ROS without the potential toxicity concerns raised about high-dose TPP compounds. SS-31 has more advanced clinical trial data, including human trials in cardiomyopathy.

Research deeper on individual longevity peptides. → Browse the Longevity Peptide Database

For educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions